Abstract:Background: Global prevalence of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease is increasing gradually, whereas approvals of successful therapeutics for central nervous system disorders are inadequate. Accumulating evidence suggests pivotal roles of the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in modulating neuroinflammation and necroptosis. Discoveries of potent small molecule inhibitors for RIPK1 with favorable pharmacokinetic properties could thus address the unmet medical needs in treating neurodegeneration. Methods: In a structure-based virtual screening, we performed site-specific molecular docking of 4,858 flavonoids against the kinase domain of RIPK1 using AutoDock Vina. We predicted physicochemical descriptors of the top ligands using the SwissADME webserver. Binding interactions of the best ligands and the reference ligand L8D were validated using replicated 500-ns Gromacs molecular dynamics simulations and free energy calculations. Results: From Vina docking, we shortlisted the top 20 flavonoids with the highest binding affinities, ranging from -11.7 to -10.6 kcal/mol. Pharmacokinetic profiling narrowed down the list to three orally bioavailable and blood-brain-barrier penetrant flavonoids: Nitiducarpin, Pinocembrin 7-O-benzoate, and Paratocarpin J. Next, trajectories of molecular dynamics simulations of the top protein-ligand complexes were analyzed for binding interactions. The root-mean-square deviation (RMSD) was 1.191 Å (±0.498 Å), 1.725 Å (±0.828 Å), 1.923 Å (±0.942 Å), 0.972 Å (±0.155 Å) for Nitiducarpin, Pinocembrin 7-O-benzoate, Paratocarpin J, and L8D, respectively. The radius of gyration (Rg) was 2.034 nm (±0.015 nm), 2.0.39 nm (± 0.025 nm), 2.053 nm (±0.021 nm), 2.037 nm (±0.016 nm) for Nitiducarpin, Pinocembrin 7-O-benzoate, Paratocarpin J, and L8D, respectively. The solvent accessible surface area (SASA) was 159.477 nm2 (±3.021 nm2), 159.661 nm2 (± 3.707 nm2), 160.755 nm2 (±4.252 nm2), 156.630 nm2 (±3.521 nm2), for Nitiducarpin, Pinocembrin 7-O-benzoate, Paratocarpin J, and L8D complexes, respectively. Therefore, lower RMSD, Rg, and SASA values demonstrated that Nitiducarpin formed the most stable complex with the target protein among the best three ligands. Finally, 2D protein-ligand interaction analysis revealed persistent hydrophobic interactions of Nitiducarpin with the critical residues of RIPK1, including the catalytic triads and the activation loop residues, implicated in the kinase activity and ligand binding. Conclusion: Our target-based virtual screening identified three flavonoids as strong RIPK1 inhibitors, with Nitiducarpin exhibiting the most potent inhibitory potential. Future in vitro and in vivo studies with these ligands could offer new hope for developing effective therapeutics and improving the quality of life for individuals affected by neurodegeneration.

Discovery of Potential RIPK1 Inhibitors by Machine Learning and Molecular Dynamics Simulations.

Inhibition of RIPK1 by ZJU-37 Promotes Oligodendrocyte Progenitor Proliferation and Remyelination Via NF-κB Pathway

Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities

Discovery, Optimization and Evaluation of Isothiazolo[5,4-B]pyridine Derivatives As RIPK1 Inhibitors with Potent in Vivo Anti-Sirs Activity

Discovery of 5‐(1‐benzyl‐1H‐imidazol‐4‐yl)‐1,2,4‐oxadiazole derivatives as novel RIPK1 inhibitors via structure‐based virtual screening

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitor: a Review of the Patent Literature (2018-Present)

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Synthesis and Characterization of Potent RIPK3 Inhibitors Based on a Tricyclic Scaffold.

Discovery of 4-Amino-1,6-dihydro-7h-pyrrolo[2,3-d]pyridazin-7-one Derivatives As Potential Receptor-Interacting Serine/threonine-Protein Kinase 1 (RIPK1) Inhibitors

Design, Synthesis and Biological Evaluation of 4-Aminoquinoline Derivatives As Receptor-Interacting Protein Kinase 2 (RIPK2) Inhibitors

Discovery of novel biaryl benzoxazepinones as dual-mode receptor-interacting protein kinase-1 (RIPK1) inhibitors

Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.

Discovery of Novel 2,8-Diazaspiro[4.5]decan-1-one Derivatives As Potent RIPK1 Kinase Inhibitors

Discovery of Potent Necroptosis Inhibitors Targeting RIPK1 Kinase Activity for the Treatment of Inflammatory Disorder and Cancer Metastasis.

Virtual screening of flavonoids as potential RIPK1 inhibitors for neurodegeneration therapy

Design, Synthesis, and Structure-Activity Relationship of Novel RIPK2 Inhibitors.

From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases

Profiling of Small-Molecule Necroptosis Inhibitors Based on the Subpockets of Kinase-Ligand Interactions.

Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor